Page 16 - Binder1

CV247 Therapy continued

Professor Andor Sebesteny has continued to research CV247 therapy and his current work is in the field of the side effects of Cisplatin, a conventional
chemotherapeutic agent, which has side effects that include toxicity to cells of the kidney. Whilst Cisplatin is an effective chemotherapeutic agent, these side‐
effects can be destructive to healthy cells of the body. One of the advantages of the CV247 therapy is that, when taken in conjunction with Cisplatin, it reduces the
toxic effects of Cisplatin. This means that not only does CV247 therapy boost the body’s immune system to help fight cancer on its own; it can also reduce the side‐
effects of other treatments.

“CV 247 supports the antioxidant processes and the immune system in the body, and thereby improves the quality of life of cancer patients and slows or stops the
progression of cancer or may even induce the regression of some tumours.

Four types of malignancies, breast, colon, prostate and lung carcinoma were selected for testing the action of CV247 therapy against its individual components and
against ascending dilutions of Cisplatin with three cell lines for each type. With flow cytometry, ATP‐TCA luminometry, sulpho‐rhodamine B assay and Crystal
Violet assay, the viability and cell toxicity of the cultures was measured by determining necrotic, apoptotic and viable cells before and after CV247 therapy
treatment. The combination of these techniques provided solid scientific evidence because the advantage of the one technique overlapped the disadvantage
of the others, and hence the results were reliable.

The results clearly supported the benefit of the combination in CV247 therapy compared with its individual components. Most exhibited an increase in dead cells
and cells apparently halted in the G2 phase of mitosis. This was in contrast to their controls, indicating a cytotoxic effect of a more gradual and sustained type than
seen with traditional cytotoxic drugs which have a rapid onset, rarely kill tumour stem cells and often inhibit tumour cells for only short periods. This was
particularly marked in LoVo colonic cancer and T47D breast cancer cell lines where CV247 was considerably more active than Na salicylate alone.”

Prof. Andor Sebesteny B.Sc. Dip.Bact. MRCVS

Qualified as a veterinary surgeon in 1960 from Bristol University and has been in practice, both full and part time ever since. Since 1964 he has also been the
veterinary supervisor of laboratory animals at the Imperial Cancer Research Fund (now CR UK), where he was until 2008 a consultant veterinary pathologist.